Ask us a question
520 547-3440
info@c-path.org
Subscribe
Home
About
HOW WE OPERATE
Breadth of Expertise
Core Competencies
Timeline
People
FAQs
Employment
Annual Reports
Education
Programs
Sharing Knowledge that Leads to Innovation
ACTIVE CONSORTIA / PROGRAMS
BmDR
Biomarker Data Repository
MSOAC
Multiple Sclerosis Outcome Assessments Consortium
CPAD
Critical Path for Alzheimer’s Disease
PRO Consortium
Patient-Reported Outcome Consortium
CPP
Critical Path for Parkinson’s
PKDOC
Polycystic Kidney Disease Outcomes Consortium
CP-RND
Critical Path for Rare Neurodegenerative Diseases
PredicTox KE
PredicTox Knowledge Environment
CP-SCD
Critical Path for Sickle Cell Disease
PSTC
Predictive Safety Testing Consortium
CPTA
Critical Path to Therapeutics for the Ataxias
QuantMed
Quantitative Medicine Program
CDRC
CURE Drug Repurposing Collaboratory
RDCA-DAP
Rare Disease Cures Accelerator-Data and Analytics Platform
DCC
Data Collaboration Center
RD-COA Consortium
Rare Disease Clinical Outcome Assessment Consortium
D-RSC
Duchenne Regulatory Science Consortium
TB-PACTS
TB-Platform for Aggregation of Clinical TB Studies
eCOA Consortium
Electronic Clinical Outcome Assessment Consortium
TTC
Transplant Therapeutics Consortium
FA-ICD
Friedreich’s Ataxia Integrated Clinical Database
TOMI-T1D
Trial Outcome Markers Initiative in T1D Consortium
HD-RSC
Huntington’s Disease Regulatory Science Consortium
TRxA
Translational Therapeutics Accelerator
INC
International Neonatal Consortium
T1D
Type 1 Diabetes Consortium
Completed Consortia
CFAST
Coalition for Accelerating Standards & Therapies
PTC
Pediatric Trials Consortium
CPTR
Critical Path to TB Drug Regimens
C-Path in Europe
Tools & Platforms
Impact
Impact Stories
Successes
Evidentiary Considerations
News & Events
Events
News
Videos
Publications
Presentations
Press Releases
Donate
News
Home
>
News & Events
>
Presentations
>
C-Path
>
Using Data to Reimagine Clinical Trials
84,109
News
November 15, 2017
PRINT
PDF
Using Data to Reimagine Clinical Trials
Related Posts
Dr. Stephenson’s presentation at University of Texas Health, San Antonio, The Perry and Ruby Stevens Parkinson’s Disease Center of Excellence: “Critical Path for Parkinson’s Collaboration to Enable Patient Focused Drug Development and Precision Medicine”
x
Contact Us
Name
Email
Phone
Message
x
Contact Us
Name
Email
Phone
Message
x
Contact Us
Name
Email
Phone
Message
x
